Accustem Sciences (ACUT) Research & Development (2021 - 2026)
Accustem Sciences (ACUT) posted quarterly Research & Development of $119525.0 for Q1 2026, up 321.66% year-over-year from $28346.0 in Q1 2025, and little changed quarter-over-quarter from $119744.0 in Q4 2025.
Accustem Sciences (ACUT) Research & Development (2021 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Research & Development for 6 consecutive years, with $119525.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 321.66% year-over-year to $119525.0; the TTM figure through Mar 2026 stood at $372193.0 (up 159.42% YoY), while the FY2025 annual figure was $281014.0, up 103.16% from the prior year.
- Research & Development was little changed at $119525.0 in Q1 2026 per ACUT's latest filing, from $119744.0 in the prior quarter.
- Across five years, Research & Development topped out at $133124.0 in Q4 2022 and bottomed at $14575.0 in Q2 2023.
- Historically, Research & Development has averaged $55615.2 across 5 years, with a median of $41972.0 in 2024.
- Annual changes were most pronounced in 2022 — Research & Development jumped 697.85% — and 2023, when it sank 73.21%.
- Accustem Sciences' Research & Development stood at $133124.0 in 2022, then plunged by 32.74% to $89535.0 in 2023, then sank by 53.12% to $41972.0 in 2024, then jumped by 185.29% to $119744.0 in 2025, then fell by 0.18% to $119525.0 in 2026.
- Business Quant data shows ACUT's Research & Development at $119525.0 in Q1 2026, $119744.0 in Q4 2025, and $72720.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 97.90 Mn |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - | 43,712.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 119,525.00 |
| Dec 31, 2025 | 119,744.00 |
| Sep 30, 2025 | 72,720.00 |
| Jun 30, 2025 | 60,204.00 |
| Mar 31, 2025 | 28,346.00 |
| Dec 31, 2024 | 41,972.00 |
| Sep 30, 2024 | 31,409.00 |
| Jun 30, 2024 | 41,746.00 |
| Mar 31, 2024 | 23,197.00 |
| Dec 31, 2023 | 89,535.00 |
| Sep 30, 2023 | 19,951.00 |
| Jun 30, 2023 | 14,575.00 |
| Mar 31, 2023 | 15,602.00 |
| Dec 31, 2022 | 133,124.00 |
| Sep 30, 2022 | 58,270.00 |
| Jun 30, 2022 | 54,396.00 |
| Mar 31, 2022 | 21,143.00 |
| Dec 31, 2021 | 26,466.00 |
| Sep 30, 2021 | 14,125.00 |
| Jun 30, 2021 | 30,198.00 |